Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2025
Long-term outcomes of biologic therapy for the treatment of prepouch ileitis: A multi-centre multi-national retrospective study.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ghersin Itai, Calini Giacomo, Koifman Eduard, Fischman Maya, Celentano Valerio, Segal Jonathan P, Argyriou Orestis, McLaughlin Simon D, Johnson Heather, Rottoli Matteo, Sahnan Kapil, Warusavitarne Janindra, Hart Ailsa L
Аннотация
AIM: Prepouch ileitis (PPI) is inflammation of the ileum proximal to an ileoanal pouch, usually associated with pouchitis. The treatment of PPI as a specific entity is poorly studied, and long-term follow-up data are lacking. We aimed to describe the long-term outcomes of biologic therapy in a large, multi-centre, multi-national cohort of patients with PPI.
METHODS: This was an observational, retrospective, multi-centre, multi-national study. We included patients with an endoscopic diagnosis of PPI, treated with biologic medications, who had a follow-up of at least 1 year after biologic treatment initiation. The primary outcome was first-line biologic treatment discontinuation during the study period. The secondary outcome was pouch failure, defined by the need for a defunctioning ileostomy and/or pouch excision.
RESULTS: There were 71 patients in our cohort. Average follow-up length was 101.1 months (±54.5 months). Infliximab was first-line treatment in 42 patients (59.2%), whereas 26 (36.6%) initially received Adalimumab and 3 (4.2%) received Vedolizumab treatment. At the end of the study period, only 16/71 patients (22.5%) were still on first-line biologic treatment. Persistence rates for infliximab (7/42, 16.7%) and adalimumab (7/26, 26.9%) were similar (p = 0.30). Out of 55 patients discontinuing first-line biologic treatment, 26 (36.6% of the cohort) developed pouch failure, and 29 (40.8%) are currently treated with a different medication.
CONCLUSION: First-line biologic treatment for PPI is associated with high rates of treatment discontinuation. A significant proportion of PPI patients initially treated with biologics develop pouch failure.
METHODS: This was an observational, retrospective, multi-centre, multi-national study. We included patients with an endoscopic diagnosis of PPI, treated with biologic medications, who had a follow-up of at least 1 year after biologic treatment initiation. The primary outcome was first-line biologic treatment discontinuation during the study period. The secondary outcome was pouch failure, defined by the need for a defunctioning ileostomy and/or pouch excision.
RESULTS: There were 71 patients in our cohort. Average follow-up length was 101.1 months (±54.5 months). Infliximab was first-line treatment in 42 patients (59.2%), whereas 26 (36.6%) initially received Adalimumab and 3 (4.2%) received Vedolizumab treatment. At the end of the study period, only 16/71 patients (22.5%) were still on first-line biologic treatment. Persistence rates for infliximab (7/42, 16.7%) and adalimumab (7/26, 26.9%) were similar (p = 0.30). Out of 55 patients discontinuing first-line biologic treatment, 26 (36.6% of the cohort) developed pouch failure, and 29 (40.8%) are currently treated with a different medication.
CONCLUSION: First-line biologic treatment for PPI is associated with high rates of treatment discontinuation. A significant proportion of PPI patients initially treated with biologics develop pouch failure.